Eligibility of outpatients with chronic heart failure for sodium-glucose co-transporter-2 inhibitors.

ABSTRACT:

Aims

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to have a relevant role in the prevention of hospitalizations for heart failure and improvement in the life expectancy of patients with diabetes and outpatients with chronic heart failure (CHF) with reduced left ventricular ejection fraction, independently from the presence of type 2 diabetes mellitus (T2DM). The aim of our study was to evaluate in a real-world population the number of outpatients with CHF who meet the enrolment criteria of the main randomized controlled trials (RCT) published in the last 5 years and consequently identify the percentage of patients who could potential benefit from SGLT2i therapy.

Methods and results

We retrospectively evaluated all consecutive outpatients referred for C

SUBMITTER: Angelini G 

PROVIDER: S-EPMC8318395 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature